PositiveID Corp., developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, has successfully created and tested a continuous glucose sensing system that measures glucose levels in individuals with diabetes.
GlucoChip is based on the proprietary chemistry platform developed by Receptors LLC, a manufacturer of smart materials products for the healthcare industry, providing a key component of the glucose-sensing microchip.
PositiveID and Receptors worked together to create the system, which integrates specifically designed synthetic materials to interact competitively with changing physiological blood glucose levels, generating a reproducible, measurable response.
“We are very proud to say that we, in conjunction with the skilled team of scientists at Receptors, have completed our goal of developing a stable and reproducible glucose-sensing system,” Scott R. Silverman, chairman and CEO of PositiveID, said stated in the press release. “By overcoming this significant hurdle in the development of GlucoChip and accomplishing this pivotal goal, the company will begin to look for major partners to accelerate the remaining development of GlucoChip, a project that has the potential to revolutionize the way people with diabetes monitor their glucose levels.”
As the company works toward optimizing the glucose-sensing system, it will focus on incorporating the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of its RFID microchip. The company said it believes this technology offers individuals with diabetes a less invasive way of monitoring their glucose levels compared to currently available systems.
GlucoChip is based on PositiveID’s FDA-cleared microchip for patient identification, the VeriChip.
For more information visit PositiveIDCorp.com
Please see disclaimer on the MissionIR website www.missionir.com/disclaimer.html